PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.64%
Revenue growth at 50-75% of META's 12.29%. Martin Whitman would worry about competitiveness or product relevance.
8.89%
Gross profit growth at 50-75% of META's 12.33%. Martin Whitman would question if cost structure or brand is lagging.
10.67%
EBIT growth similar to META's 10.27%. Walter Schloss might infer both firms share similar operational efficiencies.
10.67%
Operating income growth at 50-75% of META's 16.44%. Martin Whitman would doubt the firm’s ability to compete efficiently.
10.37%
Net income growth comparable to META's 10.17%. Walter Schloss might see both following similar market or cost trajectories.
8.33%
EPS growth at 75-90% of META's 10.47%. Bill Ackman would push for improved profitability or share repurchases to catch up.
8.33%
Diluted EPS growth at 75-90% of META's 11.04%. Bill Ackman would expect further improvements in net income or share count reduction.
0.19%
Slight or no buybacks while META is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.38%
Slight or no buyback while META is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
69.40%
OCF growth above 1.5x META's 6.39%. David Dodd would confirm a clear edge in underlying cash generation.
72.80%
Positive FCF growth while META is negative. John Neff would see a strong competitive edge in net cash generation.
3240.84%
10Y revenue/share CAGR above 1.5x META's 1223.16%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
536.65%
5Y revenue/share CAGR above 1.5x META's 190.49%. David Dodd would look for consistent product or market expansions fueling outperformance.
111.88%
3Y revenue/share CAGR 1.25-1.5x META's 77.04%. Bruce Berkowitz might see better product or regional expansions than the competitor.
No Data
No Data available this quarter, please select a different quarter.
887.09%
5Y OCF/share CAGR 1.25-1.5x META's 653.02%. Bruce Berkowitz would see if capital spending or working-capital efficiencies explain the difference.
160.19%
3Y OCF/share CAGR 1.25-1.5x META's 125.05%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
3922.02%
Net income/share CAGR 1.25-1.5x META's 2770.56%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
2621.14%
5Y net income/share CAGR above 1.5x META's 304.58%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
114.24%
3Y net income/share CAGR 50-75% of META's 194.47%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
1024.11%
5Y equity/share CAGR above 1.5x META's 101.78%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
124.53%
3Y equity/share CAGR above 1.5x META's 66.56%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.12%
AR growth is negative/stable vs. META's 14.10%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
15.19%
Inventory growth of 15.19% while META is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
7.24%
Asset growth 1.25-1.5x META's 5.19%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
6.53%
1.25-1.5x META's 5.80%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
7.05%
R&D growth drastically higher vs. META's 6.52%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
6.47%
SG&A growth well above META's 12.01%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.